F Joseph McClernon
Professor in Psychiatry & Behavioral Sciences
Joe McClernon, Ph.D. is a Professor in the Department of Psychiatry and Behavioral Sciences, Founder/Director of the Center for Addiction Science and Technology (CfAST), and Director of Evaluation and Strategic Planning in the Duke Clinical and Translational Science Institute (CTSI). He earned a Ph.D. in clinical psychology in 2001 from Southern Illinois University-Carbondale and completed a postdoctoral fellowship at Duke in 2002. He served as Director of the Addiction Division in Psychiatry and Behavioral Sciences from 2012-2020. Joe’s research is focused on increasing our understanding of tobacco and other addictions, developing new and more effective interventions to treat substance abuse, and informing the FDA’s regulation of tobacco products. He makes use of behavioral pharmacology, neuroimaging, epidemiology and clinical trial approaches in his work. He has led groundbreaking research on: the influence of drug-associated environments on drug use, relapse, and treatment; tobacco use disparities among individuals with comorbid psychiatric (e.g. ADHD) and health (e.g. HIV) problems; the role of nicotine in smoking behavior; and the evaluation of potential FDA tobacco regulatory actions. He is an active mentor having trained six postdoctoral fellows, five of which are now faculty at academic medical centers across the country. He has been continuously NIH, FDA, and foundation funded since 2002. He has authored over 150 peer-reviewed publications, has one patent, has served as Chair of NIH grant review panels, and is recipient of numerous awards including the SRNT Jarvik-Russell New Investigator Award.
Interdisciplinary Research Training Program in AIDS awarded by National Institutes of Health (Mentor). 2010 to 2025
Randomized Controlled Trial of a Novel Smoking Cessation Application Tailored to Individuals with Serious Mental Illness awarded by National Institutes of Health (Co Investigator). 2020 to 2024
Duke CTSA (TL1) awarded by National Institutes of Health (Mentor). 2018 to 2023
Mobile health interventions for varenicline adherence among HIV-positive smokers awarded by National Institutes of Health (Mentor). 2017 to 2022
Impact of new standards for tobacco products among dual e-cigarette/combusted cigarette users awarded by National Institutes of Health (Principal Investigator). 2019 to 2022
Targeting reward dysfunction as a mechanism to improve smoking cessation awarded by National Institutes of Health (Mentor). 2016 to 2022
Nicotine Withdrawal and Reward Processing: Connecting Neurobiology to Real-World Behavior awarded by National Institutes of Health (Mentor). 2017 to 2022
Project 2: Evaluating New Nicotine Standards for Cigarettes - Supplement awarded by University of Minnesota (Principal Investigator). 2017 to 2022
Early-phase Studies of a Tailored Evidence-Based Smoking Cessation mHealth App for Persons Living with HIV awarded by National Institutes of Health (Co Investigator). 2019 to 2021
Deep learning-based image analysis for assessing real-time smoking risk awarded by National Institutes of Health (Principal Investigator). 2018 to 2021
Vilardaga, Roger, et al. “Erratum to: Pilot Randomized Controlled Trial of a Novel Smoking Cessation App Designed for Individuals With Co-Occurring Tobacco Dependence and Serious Mental Illness.” Nicotine Tob Res, vol. 23, no. 2, Jan. 2021, p. 411. Pubmed, doi:10.1093/ntr/ntaa125. Full Text
Vilardaga, R., et al. “Review of Popularity and Quality Standards of Opioid-Related Smartphone Apps.” Current Addiction Reports, vol. 7, no. 4, Dec. 2020, pp. 486–96. Scopus, doi:10.1007/s40429-020-00344-6. Full Text
Pacek, Lauren R., et al. “Not Quite the Rule, But No Longer the Exception: Multiple Tobacco Product Use and Implications for Treatment, Research, and Regulation.” Nicotine Tob Res, vol. 22, no. 11, Oct. 2020, pp. 2114–17. Pubmed, doi:10.1093/ntr/ntz221. Full Text
Vilardaga, Roger, et al. “Pilot Randomized Controlled Trial of a Novel Smoking Cessation App Designed for Individuals With Co-Occurring Tobacco Use Disorder and Serious Mental Illness.” Nicotine Tob Res, vol. 22, no. 9, Aug. 2020, pp. 1533–42. Pubmed, doi:10.1093/ntr/ntz202. Full Text
Robinson, Jason D., et al. “Very Low Nicotine Content Cigarettes Disrupt the Feedback Loop of Affective States and Smoking Behavior.” Nicotine Tob Res, vol. 22, no. 8, July 2020, pp. 1294–300. Pubmed, doi:10.1093/ntr/ntz209. Full Text
Pacek, Lauren R., et al. “Cigarette Smoking and Cessation-Related Interactions With Health Care Providers in the Context of Living With HIV: Focus Group Study Findings.” J Assoc Nurses Aids Care, July 2020. Pubmed, doi:10.1097/JNC.0000000000000185. Full Text Open Access Copy
Carroll, Dana Mowls, et al. “Development and Piloting Testing of an Experimental Tobacco and Nicotine Product Marketplace.” Nicotine Tob Res, vol. 22, no. 7, June 2020, pp. 1230–34. Pubmed, doi:10.1093/ntr/ntz195. Full Text
Carroll, Dana M., et al. “Relationships between the Nicotine Metabolite Ratio and a Panel of Exposure and Effect Biomarkers: Findings from Two Studies of U.S. Commercial Cigarette Smokers.” Cancer Epidemiol Biomarkers Prev, vol. 29, no. 4, Apr. 2020, pp. 871–79. Pubmed, doi:10.1158/1055-9965.EPI-19-0644. Full Text
Pacek, Lauren R., and F. Joseph McClernon. “Risk perceptions regarding cigarette smoking in the United States continue to decline.” Drug Alcohol Depend, vol. 209, Apr. 2020, p. 107887. Pubmed, doi:10.1016/j.drugalcdep.2020.107887. Full Text
Kollins, Scott H., et al. “Increased subjective and reinforcing effects of initial nicotine exposure in young adults with attention deficit hyperactivity disorder (ADHD) compared to matched peers: results from an experimental model of first-time tobacco use.” Neuropsychopharmacology, vol. 45, no. 5, Apr. 2020, pp. 851–56. Pubmed, doi:10.1038/s41386-019-0581-7. Full Text
Sweitzer, Maggie, et al. “Neural Correlates of Social Reward Processing Differ Between Young Adult Smokers and Non-Smokers.” Neuropsychopharmacology, vol. 45, no. SUPPL 1, 2020, pp. 145–145.
Oliver, Jason, et al. “Neural Mechanisms Underlying Effects of Propranolol on Drug Cue Reactivity.” Neuropsychopharmacology, vol. 44, no. SUPPL 1, NATURE PUBLISHING GROUP, 2019, pp. 524–524.
Sweitzer, Maggie M., et al. “FEASIBILITY AND PRELIMINARY EFFECTS OF INCORPORATING SMOKING-RELATED CONTEXTS INTO AN EXTINCTION-BASED CESSATION THERAPY.” Annals of Behavioral Medicine, vol. 52, OXFORD UNIV PRESS INC, 2018, pp. S381–S381.
Engelhard, Matthew, et al. “Predicting Smoking Events with a Time-Varying Semi-Parametric Hawkes Process Model.” Mlhc, edited by Finale Doshi-Velez et al., vol. 85, PMLR, 2018, pp. 312–31.
Oliver, Jason, et al. “Increased Activation in Precuneus and Parahippocampus When Smokers View Tobacco Retail Outlets: Results of a GPS plus fMRI 'Community Neuroscience' Study.” Neuropsychopharmacology, vol. 42, NATURE PUBLISHING GROUP, 2017, pp. S325–26.
Giovacchini, Coral X., et al. “Use and Perceived Risk of Electronic Cigarettes Among North Carolina Middle and High School Students.” N C Med J, vol. 78, no. 1, 2017, pp. 7–13. Pubmed, doi:10.18043/ncm.78.1.7. Full Text
Ouyang, R. W., et al. “If you see something, swipe towards it: Crowdsourced event localization using smartphones.” Ubicomp 2013 Proceedings of the 2013 Acm International Joint Conference on Pervasive and Ubiquitous Computing, 2013, pp. 23–32. Scopus, doi:10.1145/2493432.2493455. Full Text
Vrana, Scott R., et al. “THE EFFECT OF SMOKING ON THE ACOUSTIC STARTLE RESPONSE AND PREPULSE INHIBITION PREDICTS A SUCCESSFUL QUIT ATTEMPT IN SMOKERS WITH AND WITHOUT POST-TRAUMATIC STRESS DISORDER.” Psychophysiology, vol. 50, 2013, pp. S32–S32.
McClernon, Francis J., et al. “COMBINED EMA AND GPS FOR ASSESSING THE SPATIAL DISTRIBUTION OF SMOKING BEHAVIOR: A PROOF OF CONCEPT STUDY.” Annals of Behavioral Medicine, vol. 45, SPRINGER, 2013, pp. S93–S93.
Lee, Hyoung S., et al. “RELATIONSHIP BETWEEN CHANGES IN IMPLICIT ATTITUDES TOWARD SMOKING AND SMOKING CESSATION.” Annals of Behavioral Medicine, vol. 45, SPRINGER, 2013, pp. S93–S93.